Safety and Efficacy of Bimatoprost Solution 0.03% Topical Application in Patients with Chemotherapy-Induced Eyelash Loss

The study from December 2013 assessed the safety and efficacy of bimatoprost solution 0.03% in treating patients with eyelash loss due to chemotherapy. It involved 130 participants, with 96 receiving bimatoprost and 34 receiving a placebo. The double-masked, randomized, placebo-controlled trial lasted for one year, with 89.2% of patients completing it. After 6 months, those treated with bimatoprost showed significant improvements in eyelash growth on the Global Eyelash Assessment scale and in terms of length, thickness, and darkness, as confirmed by digital image analysis. Patients initially in the placebo group experienced similar improvements upon switching to bimatoprost from months 6 to 12. The treatment was generally well-tolerated, with the most common side effects being conjunctival hyperemia, punctate keratitis, upper respiratory tract infection, and eye pruritus. The conclusion was that bimatoprost is a safe and effective treatment for chemotherapy-induced eyelash loss.